Table 5.

Incidence of adverse events and short-term neonatal outcomes

Variable*	BP-NCPAP (N = 67)	NCPAP (N = 69)	P value
Adverse events
Nasal septum breakdown [N (%)]	6 (8.9%)	9 (13%)	0.59
Eyelid edema [N (%)]	3 (4.5%)	2 (2.8%)	0.68
Feeding intolerance [N (%)]	8 (11.9%)	17 (25%)	0.08
Abdominal distension [N (%)]	16 (23.8%)	8 (12%)	0.07
Pneumothorax [N (%)]	0	0
Short-term neonatal outcomes
Mortality [N (%)]	3 (4%)	5 (7%)	0.49
New-onset sepsis after extubation [N (%)]	8 (12%)	5 (7%)	0.35
Bronchopulmonary dysplasia (oxygen dependency at 36 weeks PMA) [N (%)]	21 (31.3%)	22 (31.8%)	1.0
Necrotising enterocolitis [N (%)]	7 (10.4%)	7 (10.1%)	0.95
Grade 3/4 IVH/PVL	1/62 (1.6%)	5/65(7.7%)	0.41
ROP > stage 2 [N (%)]	11 (17%)	3 (5%)	0.02
Patent ductus arteriosus [N (%)]	36 (53.7%)	35 (51%)	0.82

*IVH = Intraventricular hemorrhage, N = Number, % = Percent, PVL = Periventricular leucomalacia, ROP = Retinopathy of prematurity